Trial Profile
Serum marker analysis of Erlotinib treatment in previously treated Non-small cell lung cancer (NSCLC) patients with and without Epidermal Growth Factor Receptor (EGFR) mutation (additional study of CJLSG0903/0904)
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 24 Dec 2018
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics
- 17 Dec 2018 Status changed from not yet recruiting to discontinued.
- 18 Jun 2011 New trial record